A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
05/2011
05/19/2011	US20110118293 Method of restoring the incretin effect
05/19/2011	US20110118292 Method of treating atherosclerosis, dyslipidemias and related conditions
05/19/2011	US20110118288 Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof
05/19/2011	US20110118286 Bicyclic heterocycle derivatives and their use as gpcr modulators
05/19/2011	US20110118284 Thienopyrimidine compounds
05/19/2011	US20110118282 Soluble Guanylate Cyclase Activators
05/19/2011	US20110118280 Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
05/19/2011	US20110118275 OXAZOLO[4,5-c]PYRIDINE SUBSTITUTED PYRAZINE
05/19/2011	US20110118266 Derivatives of triazines and uracils, their preparation and their application in human therapeutics
05/19/2011	US20110118261 Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
05/19/2011	US20110118259 Benzimidazole derivatives and their use for modulating the gabaa receptor complex
05/19/2011	US20110118251 Spiropiperidine compounds as orl-1 receptor antagonists
05/19/2011	US20110118248 Heteroaryl sulfonamides and CCR2/CCR9
05/19/2011	US20110118245 Raf kinase modulator compounds and methods of use thereof
05/19/2011	US20110118241 6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2
05/19/2011	US20110118231 Modulators of 5-ht receptors and methods of use thereof
05/19/2011	US20110118228 Enzymatic production or chemical synthesis and uses for 5,7-dienes and UVB conversion products thereof
05/19/2011	US20110118211 Novel glucokinase activators and methods of using same
05/19/2011	US20110118204 Nutritional composition with free amino acids and structured lipids
05/19/2011	US20110118186 Synthetic peptide amides and dimeric forms thereof
05/19/2011	US20110118182 Process for the extraction, purification and enzymatic modification of soy 7s globulin alpha' subunit for use as hypocholesterolemizing agent
05/19/2011	US20110118181 Pcsk9 inhibitors and methods of use thereof
05/19/2011	US20110118180 Method of treatment of diabetes type 2 comprising add-on therapy to metformin
05/19/2011	US20110118178 Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
05/19/2011	US20110118177 Biotechnological production of cyanophycin dipeptides
05/19/2011	US20110118173 Method of delipidation of hdl using serum opacity factor to prevent, inhibit, and/or reverse atherosclerosis
05/19/2011	US20110118172 Metastin derivative and use thereof
05/19/2011	US20110117226 Uses of conglutin-gamma
05/19/2011	US20110117187 Topical compositions and methods for epithelial-related conditions
05/19/2011	US20110117184 Compositions for mucosal delivery of agents
05/19/2011	US20110117180 Vegetarian microcapsules
05/19/2011	US20110117143 TREATMENT OF CELIAC DISEASE WITH IgA
05/19/2011	US20110117136 Dehydroepiandrosterone production promoter and use thereof
05/19/2011	US20110117095 Growth factor htter36
05/19/2011	US20110117093 Antibodies that immunospecifically bind to b lymphocyte stimulator protein
05/19/2011	US20110117089 BCR-Complex-Specific Antibodies And Methods Of Using Same
05/19/2011	US20110117084 Vandetanib derivatives
05/19/2011	US20110117076 Method for Preparing Raw Material for Functional Foods from Barley or Wheat Seeds
05/19/2011	US20110117069 Method for activating regulatory t-cells
05/19/2011	US20110117066 Established human brown adipocyte line and method for differentiation from an hmads cell line
05/19/2011	US20110117064 Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same
05/19/2011	US20110117049 Methods and Compositions for Modulating Adipocyte Function
05/19/2011	US20110117021 Fully human anti-vap-1 monoclonal antibodies
05/19/2011	DE102009053562A1 Pharmaceutical composition, useful for treating diabetes mellitus type 2 in a combination therapy with other antidiabetic agent, comprises rosiglitazone succinate as an active agent
05/19/2011	CA2780683A1 Therapeutic or prophylactic agent for diabetes
05/19/2011	CA2780460A1 Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
05/19/2011	CA2780382A1 Pemirolast for the treatment of systemic low grade inflammation
05/19/2011	CA2780243A1 Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites
05/19/2011	CA2780043A1 Pharmaceutical composition comprising a glp-1 agonist and methionine
05/19/2011	CA2779508A1 Method and compositions for treating disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine d2l receptor
05/19/2011	CA2779088A1 [1,5]-diazocin derivatives
05/19/2011	CA2778886A1 N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
05/19/2011	CA2778175A1 8-azabicyclo[3.2.1]octane-8-carboxamide derivative
05/18/2011	EP2322642A2 Arachidonic acid and methods for the production and use thereof
05/18/2011	EP2322641A2 Arachidonic acid and methods for the production and use thereof
05/18/2011	EP2322640A2 Arachidonic acid and methods for the production and use thereof
05/18/2011	EP2322601A1 Method of collecting placental stem cells
05/18/2011	EP2322545A1 Analogues of GLP-1
05/18/2011	EP2322521A1 Heteroaryl compounds useful as inhibitors of GSK-3
05/18/2011	EP2322506A1 Histamine H3 receptor agents, preparation and therapeutic uses
05/18/2011	EP2322505A1 1-adamantylazetidin-2-one derivative and pharmaceutical preparation comprising same
05/18/2011	EP2322229A2 Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
05/18/2011	EP2322199A1 Growth differentiation factor receptors, and methods of using same
05/18/2011	EP2322192A1 Active agent preparation
05/18/2011	EP2322185A2 Polynucleotide therapy
05/18/2011	EP2322175A1 Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof
05/18/2011	EP2322174A2 Combined use of valsartan and calcium channel blockers for therapeutic purposes
05/18/2011	EP2322162A1 5HT2C receptor modulator compositions and methods of use
05/18/2011	EP2322157A1 Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
05/18/2011	EP2322156A1 Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
05/18/2011	EP2322154A2 Methods for detecting and clearing cross beta structure comprising proteins with crossbeta structure binding compounds.
05/18/2011	EP2322152A1 Method of preparing a composition comprising a GPR119 agonist
05/18/2011	EP2322151A2 Sustained release formulation comprising a GPR119 agonist and a DPP-IV inhibitor
05/18/2011	EP2322150A2 Method of identifying GLP-1 secretagogues
05/18/2011	EP2321640A1 Formulation for oral administration of proteins
05/18/2011	EP2321317A1 Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
05/18/2011	EP2321308A1 Piperidine gpcr agonists
05/18/2011	EP2321305A1 Heterocyclic gpcr agonists
05/18/2011	EP2321297A1 Piperidinyl gpcr agonists
05/18/2011	EP2321295A2 4-(pyridin-4-yl)-1h-[1,3,5]triazin-2-one derivatives as gsk3-beta inhibitors for the treatment of neurodegenerative diseases
05/18/2011	EP2321287A1 4,5-dihydro-oxazol-2-yl derivatives
05/18/2011	EP2321282A1 New benzimidazole derivatives
05/18/2011	EP2321276A1 New compounds vii
05/18/2011	EP2320919A1 Large-scale process for the preparation of thylakoids
05/18/2011	EP2320910A1 Chemical compounds and uses
05/18/2011	EP2320738A1 Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
05/18/2011	EP2040755B1 Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
05/18/2011	EP1984324B1 Mandelic hydrazides
05/18/2011	EP1767201B1 Nutrient composition and composition for prevention/mitigation of digestive tract depression
05/18/2011	EP1581221B1 Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
05/18/2011	EP1295871B1 Vitamin d derivatives possessing a 22-oxa or 22-thia atom, a c17-side chain substituted by an acid, ester or amide group and a 16(17)-double bond
05/18/2011	EP1268096B9 Extrusion die
05/18/2011	CN1899331B Extract of aceraceous plant and its extracting method and use
05/18/2011	CN1798831B Compositions comprising lactobacillus plantarum strains in combination with tannin and new lactobacillus plantarum strains
05/18/2011	CN1665554B Compounds and method for preparing surfaces in a haemocompatible manner
05/18/2011	CN1527704B Compositions and method of administering tubulin binding agents for the treatment of ocular diseases
05/18/2011	CN102066945A Modulators of STAT3 signalling
05/18/2011	CN102066420A 1d05 pcsk9 antagonists
05/18/2011	CN102066372A 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
05/18/2011	CN102066342A Quinoxalinedione derivatives

1 ... 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 ... 1298